<DOC>
	<DOCNO>NCT02107391</DOCNO>
	<brief_summary>The purpose study determine whether DCVAC/PCa add onto hormone therapy improve PSA progression time patient Metastatic Prostate Cancer .</brief_summary>
	<brief_title>Phase II Study DCVAC/PCa Added Hormone Therapy Men With Metastatic Prostate Cancer</brief_title>
	<detailed_description>Use vaccine improve Prostate Specific Antigen ( PSA ) level .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Male 18 year old Histologically confirm prostate adenocarcinoma Presence bone soft tissue metastasis ( CT PET MRI and/or scintigraphy ) Androgen deprivation therapy use Luteinizinghormonereleasing hormone ( LHRH ) analogues commence least one month three month prior randomization orchiectomy perform least one month three month prior randomization Serum testosterone level screening ( ≤ 1.7 nmol/l , resp . ≤ 50 ng/dL ) Eastern Cooperative Oncology Group ( ECOG ) 02 Confirmed brain and/or leptomeningeal metastases Prior ongoing chemotherapy prostate cancer Peripheral neuropathy Common Toxicity Criteria ( CTC ) grade 2 great Other uncontrolled intercurrent illness Treatment immunotherapy prostate cancer Clinically significant cardiovascular disease Active autoimmune disease require treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Biological</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Androgen Deprivation Therapy</keyword>
</DOC>